A Single Arm, Open Label, Single Dose and Multiple Dose Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects
Latest Information Update: 19 Dec 2022
At a glance
- Drugs 101-PGC-005 (Primary)
- Indications COVID 2019 infections
- Focus Pharmacokinetics
- Sponsors 101 Therapeutics
- 13 Dec 2022 Planned End Date changed from 15 Nov 2022 to 15 Jan 2023.
- 23 Nov 2022 New trial record